Published in:
Open Access
01-12-2005 | Case report
Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives
Authors:
Xavier Durando, Emilie Thivat, Michel D'Incan, Anne Sinsard, Jean-Claude Madelmont, Philippe Chollet
Published in:
BMC Cancer
|
Issue 1/2005
Login to get access
Abstract
Background
Median survival of metastatic malignant melanoma is 6.0 to 7.5 months, with a 5-year survival of ~6.0%. Although long-term complete remissions are rare, few reports describe cases after chemotherapy. Fifty-three patients with metastatic melanoma were treated with Cystemustine, a chloroethyl nitrosourea (CENU) (60 or 90 mg/m2).
Case presentation
We describe 5 cases, presenting with complete response with long-term disease-free survival of long-term remission of 14, 12, 9, 7 and 6 years after Cystemustine therapy alone.
Conclusion
Long-term survival has already been described in literature, but in all cases they have been obtained after chemotherapy associated with or followed by surgery. But despite these noteworthy and encouraging but also rare results, it appears essential to increase cystemustine efficiency.